Literature DB >> 573408

Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis.

H Hasegawa, J C Allen, B M Mehta, W R Shapiro, J B Posner.   

Abstract

Intracarotid (i.c.) hyperosmolar mannitol enhances central nervous system (CNS) penetration of intravenous (i.v.) methotrexate (MTX) in normal adult rats. A fivefold augmentation in the CSF:serum and ipsilateral brain:serum MTX concentration ratios was observed 1 hour after drug administration. Intravenous mannitol had no such effect. Rats with meningeal carcinomatosis have a partial defect in blood-brain barrier function, and the CSF:serum MTX concentration ratio was 4.6 times higher in these animals than in normal rats prior to mannitol therapy. Intracarotid hyperosmolar mannitol further augmented the blood-brain barrier permeability to intravenous MTX. Intracarotid mannitol increased the therapeutic effect of MTX, since rats with meningeal carcinomatosis that received i.v. MTX and i.c. mannitol experienced a slight enhancement in survival.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 573408     DOI： 10.1212/wnl.29.9_part_1.1280

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  10 in total

1.  Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.

Authors:  E A Neuwelt; S A Dahlborg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  Enhanced cerebrovascular permeability by Metrazol: significance for brain metastases.

Authors:  N Greig; K Hellmann
Journal:  Clin Exp Metastasis       Date:  1983 Jan-Mar       Impact factor: 5.150

Review 3.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 4.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  Chemotherapy of malignant gliomas.

Authors:  Y Ushio; T Hayakawa; H Hasegawa; K Yamada; N Arita
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

6.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

7.  The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.

Authors:  J Allen; G Rosen; H Juergens; B Mehta
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Uptake of liposomally entrapped adenosine-3'-5'-cyclic monophosphate in mouse brain.

Authors:  Ivone Gomes; Shail K Sharma
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

9.  A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group.

Authors:  S J Bertolone; E S Baum; W Krivit; G D Hammond
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

10.  The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80.

Authors:  M N Azmin; J F Stuart; A T Florence
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.